Products from BPS Bioscience require a minimum order value above 400€
Applications: Screen or titrate small molecule inhibitors or biologics for drug discovery and high-throughput screening (HTS) applications of the TL1A binding to DcR3.
Background: Decoy receptor 3 (DcR3) is a soluble receptor of the tumor necrosis factor receptor superfamily of proteins (TNFRSF), which associates with its respective ligands, such as TL1A, FasL and LIGHT. DcR3 has been recognized as a significant anti-apoptotic factor with prominent involvement in various inflammatory and neoplastic conditions. Increased intratumor expression of DcR3 and elevated soluble DcR3 protein content in the sera of patients has been reported for various malignancies. TL1A, also called TNFSF15, is a member of the tumor necrosis factor family. It is expressed in different immune cells, such as monocyte, macrophage, dendritic cell, T cell and non-immune cells. TL1A competitively binds to DcR3, providing stimulatory signal for downstream signaling pathways, and then regulates proliferation, activation, apoptosis, and chemokine production in effector cells. Inhibition of DcR3-TL1A interaction has substantial therapeutic potential.
Contraindications: The final concentration of DMSO in the assay should not exceed 1%.
Description: The DcR3:TL1A Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of the interaction between DcR3 (Decoy Receptor 3) and TL1A (TNF-like ligand 1A). This kit comes in a convenient 96-well format, with biotin-labeled TL1A, purified DcR3, streptavidin-labeled HRP, and assay buffer for 100 binding reactions.First, DcR3 is coated on a 96-well plate. Next, biotinylated TL1A is incubated with DcR3. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence. The chemiluminescence signal is proportional to the binding of DcR3:TL1A.
Storage Stability: This assay kit will perform optimally for up to 6 months from date of receipt when the materials are stored as directed.
Warnings: Avoid freeze/thaw cycles
Biosafety Level: Not applicable (BSL-1)
References: Lagou,S., et al., 2022 Cancer Diagn. Progn. 2(4): 411-421.
Xu, W.-D., et al., 2022 Front. Immunol. 13: 1-10.